AARDEX Group

Partners -- !>

Meet our Adherence Ecosystem

Untitled design (28)

Powering Clinical Trial Success Through Collaboration

AARDEX Group is dedicated to advancing clinical research and improving patient outcomes through our innovative solutions for measuring and managing medication adherence. We recognize that clinical trials are complex endeavors requiring multiple stakeholders' involvement, each with unique expertise and capabilities. That's why we have built an ecosystem of partners who share our vision and commitment to improving patient outcomes through clinical trial success.

Our ecosystem includes some of the most prominent and respected names in the industry, including CMOs, CROs, EDC, IRT, DCT vendors, and several industry-leading adherence packaging and device developers. By collaborating with these partners, AARDEX Group is leading the way in streamlining the approach to measuring and managing adherence in various clinical trial settings, including site-based, hybrid, and decentralized.

Our partners bring a wealth of knowledge and expertise to the table. By working together, we can develop innovative solutions that address the unique challenges of clinical trial adherence management. Our collective efforts are transforming how medication adherence is measured and managed, resulting in more accurate data and improved patient outcomes.

At AARDEX Group, we are proud to be part of a network of partners that is making a significant impact on the field of clinical research. Our commitment to advancing clinical trial success through collaboration and innovation is unwavering, and we look forward to continuing to work with our partners to improve the lives of patients everywhere.

Adherence Packaging and Devices

medmix logo
Schreiner Medipharm logo
BIOCORP Logo
Etectrx logo
Pill Connect Logo
Westrock Logo

IRT & RTSM

Signant Health Logo
Endpoint Clinical Logo
Suvoda Logo
Premier Research Logo

Contract Manufacturing Organizations

Thermofisher Logo
catalent logo
PCI Pharma Services Logo

Decentralized Clinical Trials

Clinpal logo
Xclinical Logo
Medable logo
THREAD Research Logo

Electronic Data Capture

Medidata logo
Oracle logo

Research Partners

WEBINAR WITH MERCK & BIOGEN

Mitigating the Risk of Poor Adherence in Trials

Watch this live recording with adherence experts from Merck & Biogen to learn about their approach to mitigating the risk of poor adherence in trials.

Untitled design (28)

FROM THE AARDEX GROUP BLOG

Featured Adherence Content

We are thrilled to feature expert insights from Bernard Vrijens, a world-renowned expert on medication adherence. Taking medication as prescribed is crucial to achieving optimal health outcomes, yet non-adherence is a prevalent issue. Bernard Vrijens' extensive research and experience in the field provide invaluable insights into the factors that contribute to medication non-adherence and effective strategies to address them. His contributions to our medication adherence blog offer actionable advice and evidence-based recommendations to improve medication adherence and ultimately, patient outcomes.

Adherence in clinicat trials

Let us first recognise the enormity of the challenges we are facing, on a global scale, when it comes to cancer. It is estimated that there were 18.1 million new cases of cancer worldwide in 2020, with around 10 million

Read More »
Press Release

AARDEX Group, the global leader in medication adherence solutions, has today announced a collaboration agreement with Compliance Meds Technologies (CMT), a mobile-health technology solutions provider. In this cooperation, the partners will combine the AARDEX MEMS® Adherence Software with CMT’s CleverCap®

Read More »
Medication Adherence in Chronic Disease Management

Medication adherence is a vital component in managing chronic diseases effectively. However, it remains a significant challenge, with non-adherence rates reaching up to 50% among patients. This lack of adherence results in poor health outcomes and increased burdens on healthcare

Read More »

In a recent paper titled ‘The impacts of undetected nonadherence in phase II, III and post-marketing clinical trials: An overview’ the authors detailed the findings of a research project which aimed to provide an overview of the consequences of unrecognized

Read More »

Clearly it is in no one’s interests for a clinical trial to fail. Whenever these high-stake activites are abandoned and drug development pathways are aborted, missed opportunities abound. Beyond the sponsor’s missed commercial opportunity, there are missed opportunities to advance

Read More »

In a clinical trial, every piece of data contributes to the overall story being told. No matter how small or seemingly insignificant, all the information that emerges over the course of the process adds rich detail to the narrative. Outcome

Read More »